Literature DB >> 28885300

Use of Smoking Cessation Methods Among Patients Receiving Office-based Buprenorphine Maintenance Treatment.

Pooja A Shah1, Chinazo O Cunningham, Mia T Brisbane, Joseph P DeLuca, Shadi Nahvi.   

Abstract

OBJECTIVES: Provision of smoking-cessation treatment is limited in office-based buprenorphine maintenance treatment (BMT) settings. This study describes smoking and smoking-cessation behaviors among patients receiving office-based BMT.
METHODS: Cross-sectional study of patients receiving office-based BMT at a community health center in the Bronx, NY. We interviewed patients assessing sociodemographic, and substance use and tobacco use characteristics, including methods used for smoking cessation. We reported simple frequencies and explored associations of BMT characteristics with smoking behaviors.
RESULTS: Of 68 patients, 87.7% were current cigarette smokers, 7.9% were former smokers, and 4.4% had never smoked. Of lifetime smokers, 83.1% reported at least 1 prior quit attempt, and 78.5% had used medication (75.4% used nicotine replacement therapy, 29.2% varenicline, and 9.2% bupropion). Ten patients (15.4%) reported using electronic cigarettes to try to quit smoking. Stopping "cold turkey" (40.0%) and gradually decreasing the number of cigarettes smoked (32.3%) were nonpharmacological methods of quitting tried most often. Use of behavioral support, including stop-smoking programs and counseling, was low. Higher dose and longer duration of BMT was associated with greater smoking frequency.
CONCLUSIONS: Patients receiving BMT have a high prevalence of cigarette smoking, though most have tried to quit, and have prior experience with pharmacotherapy for smoking cessation. Efforts to optimize smoking-cessation treatments among BMT patients are needed.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28885300      PMCID: PMC5659878          DOI: 10.1097/ADM.0000000000000356

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  27 in total

1.  How is tobacco treatment provided during drug treatment?

Authors:  Jamie J Hunt; A Paula Cupertino; Susan Garrett; Peter D Friedmann; Kimber P Richter
Journal:  J Subst Abuse Treat       Date:  2011-08-09

2.  Tobacco use and quit attempts among methadone maintenance clients.

Authors:  K P Richter; C A Gibson; J S Ahluwalia; K H Schmelzle
Journal:  Am J Public Health       Date:  2001-02       Impact factor: 9.308

3.  Current Cigarette Smoking Among Adults - United States, 2005-2015.

Authors:  Ahmed Jamal; Brian A King; Linda J Neff; Jennifer Whitmill; Stephen D Babb; Corinne M Graffunder
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-11-11       Impact factor: 17.586

4.  Cigarette Smoking Is Associated With Increased Risk of Substance Use Disorder Relapse: A Nationally Representative, Prospective Longitudinal Investigation.

Authors:  Andrea H Weinberger; Jonathan Platt; Hannah Esan; Sandro Galea; Debra Erlich; Renee D Goodwin
Journal:  J Clin Psychiatry       Date:  2017-02       Impact factor: 4.384

5.  Smoking cessation treatment in community-based substance abuse rehabilitation programs.

Authors:  Malcolm S Reid; Bryan Fallon; Susan Sonne; Frank Flammino; Edward V Nunes; Huiping Jiang; Eva Kourniotis; Jennifer Lima; Ron Brady; Cynthia Burgess; Cynthia Arfken; Eric Pihlgren; Louis Giordano; Aron Starosta; James Robinson; John Rotrosen
Journal:  J Subst Abuse Treat       Date:  2007-10-24

6.  Buprenorphine treatment in an urban community health center: what to expect.

Authors:  Chinazo Cunningham; Angela Giovanniello; Galit Sacajiu; Susan Whitley; Pamela Mund; Robert Beil; Nancy Sohler
Journal:  Fam Med       Date:  2008 Jul-Aug       Impact factor: 1.756

7.  Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort.

Authors:  R D Hurt; K P Offord; I T Croghan; L Gomez-Dahl; T E Kottke; R M Morse; L J Melton
Journal:  JAMA       Date:  1996-04-10       Impact factor: 56.272

8.  Cigarette smoking and interest in quitting in methadone maintenance patients.

Authors:  Shadi Nahvi; Kimber Richter; Xuan Li; Laxmi Modali; Julia Arnsten
Journal:  Addict Behav       Date:  2006-02-13       Impact factor: 3.913

9.  Tobacco addiction and smoking status in heroin addicts under methadone vs. buprenorphine therapy.

Authors:  Benedetta Pajusco; Cristiano Chiamulera; Gianluca Quaglio; Luca Moro; Rebecca Casari; Gabriella Amen; Marco Faccini; Fabio Lugoboni
Journal:  Int J Environ Res Public Health       Date:  2012-03-16       Impact factor: 3.390

10.  Current cigarette smoking among adults - United States, 2005-2012.

Authors:  Israel T Agaku; Brian A King; Shanta R Dube
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-01-17       Impact factor: 17.586

View more
  5 in total

Review 1.  Achieving Smoking Cessation Among Persons with Opioid Use Disorder.

Authors:  Cynthia Vlad; Julia H Arnsten; Shadi Nahvi
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

2.  Pilot Tobacco Treatment Intervention for Women in Residential Treatment for Substance Use Disorder.

Authors:  Amanda Fallin-Bennett; Janine Barnett; Letitia Ducas; Amanda T Wiggins; Andrea McCubbin; Kristin Ashford
Journal:  J Obstet Gynecol Neonatal Nurs       Date:  2018-09-28

3.  The impact of menthol cigarette use on quit attempts and abstinence among smokers with opioid use disorder.

Authors:  Danusha Selva Kumar; Meghan Peterson; Chenshu Zhang; Pebbles Fagan; Shadi Nahvi
Journal:  Addict Behav       Date:  2021-02-23       Impact factor: 4.591

4.  Self-Rated Physical Health and Unmet Healthcare Needs among Swedish Patients in Opioid Substitution Treatment.

Authors:  Katja Troberg; Anders Håkansson; Disa Dahlman
Journal:  J Addict       Date:  2019-04-15

5.  Text-messaging to promote smoking cessation among individuals with opioid use disorder: quantitative and qualitative evaluation.

Authors:  Divya Shankar; Belinda Borrelli; Vinson Cobb; Lisa M Quintiliani; Tibor Palfai; Zoe Weinstein; Katia Bulekova; Hasmeena Kathuria
Journal:  BMC Public Health       Date:  2022-04-06       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.